Pfizer Inc. (NYSE:PFE) Announces Quarterly Dividend of $0.43

Pfizer Inc. (NYSE:PFE - Get Free Report) announced a quarterly dividend on Wednesday, June 25th, RTT News reports. Investors of record on Friday, July 25th will be paid a dividend of 0.43 per share by the biopharmaceutical company on Tuesday, September 2nd. This represents a $1.72 dividend on an annualized basis and a yield of 7.08%.

Pfizer has a payout ratio of 55.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Pfizer to earn $3.03 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 56.8%.

Pfizer Stock Performance

NYSE PFE traded down $0.02 during trading on Wednesday, reaching $24.29. The company's stock had a trading volume of 25,591,071 shares, compared to its average volume of 41,231,266. Pfizer has a twelve month low of $20.92 and a twelve month high of $31.54. The firm has a market cap of $138.10 billion, a price-to-earnings ratio of 17.60, a P/E/G ratio of 0.87 and a beta of 0.57. The business's fifty day moving average price is $23.33 and its 200-day moving average price is $24.87. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the business posted $0.82 EPS. The company's revenue was down 7.8% on a year-over-year basis. As a group, analysts anticipate that Pfizer will post 2.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

A hedge fund recently raised its stake in Pfizer stock. Revolve Wealth Partners LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,766 shares of the biopharmaceutical company's stock after acquiring an additional 2,087 shares during the period. Revolve Wealth Partners LLC's holdings in Pfizer were worth $498,000 at the end of the most recent quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PFE shares. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.